ClinicalTrials.gg
RecruitingNCT07024784Updated Oct 1, 2026

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

A Phase 2 interventional study of IMGN151 and Carboplatin in Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer and Fallopian Tube Cancer, sponsored by AbbVie. Recruiting at 21 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Oct 1, 20266 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
377
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Fallopian Tube Neoplasms by AbbVie — 5 open to participants now, 8 under way, 1 of them phase 3. Fallopian Tube Neoplasms · AbbVie.

Planned enrollment
3rd of 12
377 · median 198
Started
2025
with 2 others
Phase 2
5 of 14
3 open now
Registered
12th of 14
by date

Among the 14 studies in Fallopian Tube Neoplasms by AbbVie, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 2, and was the 12th registered.

Fallopian Tube Neoplasms

835 studies on the registry are indexed under Fallopian Tube Neoplasms; 131 are open to participants now.

Browse Fallopian Tube Neoplasms studies →

Open to participants now

5 of the 14 studies in Fallopian Tube Neoplasms by AbbVie are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 106 Fallopian Tube Neoplasms studies recruiting now, 88 (83%) set no upper age limit and 10 (9%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Fallopian Tube Neoplasms by AbbVie, or all of them as a file.
02

Study summary

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies in adult participants with gynecologic cancers.

IMGN151 is an investigational drug being developed for the treatment of gynecologic cancers. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. Around 377 participants with gynecologic cancers will be enrolled in the study at approximately 50 sites worldwide.

Participants will receive intravenous infusions of IMGN151 as monotherapy or in combination with anti-cancer therapies according to their assigned study arm. In Arm A, participants will receive IMGN151 in combination with carboplatin on Day 1 of each cycle. In Arm B, participants will receive IMGN151 in combination with olaparib, twice a day (BID) on Day 1 of each cycle. In Arm C, participants will receive IMGN151 in combination with bevacizumab on Day 1 of each cycle. In Arm D, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm E, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm F, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. The total study duration will be approximately 3 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

03

Conditions studied

  • Gynecologic Cancers
  • Platinum-Sensitive Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer (PSOC)

Keywords

  • Gynecologic Cancers
  • Platinum-Sensitive Ovarian Cancer
  • Platinum-Resistant Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer (PSOC)
  • Cancer
  • IMGN151
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • performance status of 0 or 1
  • Participants (except for platinum-sensitive ovarian, fallopian tube, and primary peritoneal cancer (PSOC) participants without disease progression after platinum combination standard of care therapy in Arms B and D) will have ≥ 1 lesion that meets the definition of by v1.1 (radiographically measured by the investigator).
  • Participants will have high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC).
  • Participant has completed prior therapy within the specified times below:

    • Systemic antineoplastic therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of IMGN151.
    • Focal radiation completed ≥ 2 weeks prior to the first dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Participants with ovarian cancer with histologies including: endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, as well a low-grade or borderline ovarian tumor.
  • History of medical conditions or any other reason that the investigator determines would interfere with the participant's participation in this study or would make the participant an unsuitable candidate to receive study treatment.
  • Prior treatment with FRα-targeting therapy.
  • Prior wide-field radiotherapy affecting more than 20% of the bone marrow.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
377 participants (estimated)

Study arms

  • Experimental
    Arm A: IMGN151 + Carboplatin (For PSOC)

    Participants will receive IMGN151 in combination with Carboplatin on Day 1 of a 21-day cycle.

    Drug: IMGN151 · Drug: Carboplatin

  • Experimental
    Arm B: IMGN151 + Olaparib (For PSOC)

    Participants will receive IMGN151 in combination with Olaparib twice a day (BID) on Day 1 of a 21-day cycle.

    Drug: IMGN151 · Drug: Olaparib

  • Experimental
    Arm C: IMGN151 + Bevacizumab (For PSOC or PROC)

    Participants will receive IMGN151 in combination with Bevacizumab Day 1 of a 21-day cycle.

    Drug: IMGN151 · Drug: Bevacizumab

  • Experimental
    Arm D: IMGN151 Monotherapy (For PSOC)

    Participants will receive IMGN151 Day 1 of a 21-day cycle.

    Drug: IMGN151

  • Experimental
    Arm E: IMGN151 Monotherapy (For PROC in China)

    Participants will receive IMGN151 Day 1 of a 21-day cycle.

    Drug: IMGN151

  • Experimental
    Arm F: IMGN151 Monotherapy (For PROC in Japan)

    Participants will receive IMGN151 Day 1 of a 21-day cycle.

    Drug: IMGN151

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicities (DLTs)

    Dose limiting toxicities (DLTs) of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.

    Time frame: Up to approximately 3 years

  2. Percentage of Participants with Adverse Events (AE)

    An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Objective Response (OR)

    Defined as achieving confirmed response (complete response \[CR\] + partial response \[PR\]) assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1.

    Time frame: Up to approximately 3 years

  2. Duration of response (DOR)

    Defined as the time from initial response of CR or PR until investigator assessed radiographical PD per RECIST v1.1 or death of any cause, whichever occurs first.

    Time frame: Up to approximately 3 years

  3. Progression-free survival (PFS)

    Defined as the time from the randomization date for randomized phase or the first dose of study treatment for non-randomized phase until investigator-assessed radiographical PD per RECIST v1.1 or death of any cause, whichever occurs first.

    Time frame: Up to approximately 3 years

07

Study locations

21 of 21 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jan 2028, 30 months after the start.

Of 125 phase 2 interventional studies under Fallopian Tube Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2025
First posted
Jun 17, 2025
StartActual
Jul 30, 2025
Primary completionEst.
Jan 2028
CompletionEst.
Feb 2028
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added, 1 site removed
Show 6 added (5 United States, 1 Japan)
  • Start Los Angeles /ID# 281533 · Los Angeles, United States
  • University of Colorado Hospital- Aurora /ID# 278232 · Aurora, United States
  • University Of Minnesota /ID# 277850 · Minneapolis, United States
  • SUNY Upstate Medical University - Syracuse /ID# 277305 · Syracuse, United States
  • University Hospitals Cleveland Medical Center /ID# 279601 · Cleveland, United States
  • The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 276711 · Koto-ku, Japan
Show 1 removed
  • The Cancer Institute Hospital Of JFCR /ID# 276711 · Koto-ku, Japan
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    6 sites added, 1 site removed
    Show 6 added (5 United States, 1 Japan)
    • Start Los Angeles /ID# 281533 · Los Angeles, United States
    • University of Colorado Hospital- Aurora /ID# 278232 · Aurora, United States
    • University Of Minnesota /ID# 277850 · Minneapolis, United States
    • SUNY Upstate Medical University - Syracuse /ID# 277305 · Syracuse, United States
    • University Hospitals Cleveland Medical Center /ID# 279601 · Cleveland, United States
    • The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 276711 · Koto-ku, Japan
    Show 1 removed
    • The Cancer Institute Hospital Of JFCR /ID# 276711 · Koto-ku, Japan
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07024784
Lead sponsor
AbbVie
Collaborators
GOG Foundation
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Jul 30, 2025
Primary completion
Jan 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion